CDEK
← All drugs Report issue

hydroxystilbamidine isetionate

Small moleculeapproved

Approved

Dec 22, 1953

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1950s

  1. Dec 22, 1953

    Sanofi-Aventis — Earliest FDA Approval

  2. Dec 22, 1953

    Sanofi-Aventis — NDA Secondary Org

  3. Dec 22, 1953

    Sanofi-Aventis — NDA Organization

Indications

Approved for

Mechanism of action

  • RNAINHIBITOR

    RNA inhibitor

  • DNAINHIBITOR

    DNA inhibitor

Approval history

  • approvedDec 22, 1953

Chemistry & pharmacology

Loading structure…

SMILES

N=C(N)c1ccc(/C=C/c2ccc(C(=N)N)cc2O)cc1.O=S(=O)(O)CCO.O=S(=O)(O)CCO
Mol. weight
532.6 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 2-hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulphonate) (salt)
  • 2-hydroxy-4,4'-stilbenedicarboxamidine bis(2-hydroxyethanesulphonate) (salt)
  • hsb
  • hsb
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isethionate
  • hydroxystilbamidine isetionate
  • hydroxystilbamidine isetionate
  • hydroxystilbamidine isetionate
  • oxistilbamidine isethionate
  • oxistilbamidine isethionate

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
Sanofi-AventisFor profitNDA2Dec 22, 1953
Sanofi-AventisFor profitNDADec 22, 1953